Skip to content

Company · founded 1997

Indoor Biotechnologies (United States)

Charlottesville, United States · inbio.com

Manage this page

Citations, last 5 years: 51
Works, last 5 years: 18
h-index: 80
Scientists listed: 1
Grants since 2016: 12

Grants received

2009–2020 · research · R01

Antigenic determinants of asthma-associated allergens for design of immunotherapy.

Martin D. Chapman · Indoor Biotechnologies (United States) · funded by National Institutes of Health

$470kAllergic Rhinitis and Sensitization

2009–2020 · research · R01

Antigenic determinants of asthma-associated allergens for design of immunotherapy.

Martin D. Chapman · Indoor Biotechnologies (United States) · funded by National Institutes of Health

$100.3kAllergic Rhinitis and Sensitization

2009–2026 · research · R01

Antigenic determinants of asthma-associated allergens for design of immunotherapy

Martin D. Chapman · Indoor Biotechnologies (United States) · funded by National Institutes of Health

$528.6kAllergic Rhinitis and Sensitization

2009–2025 · research · R01

Antigenic determinants of asthma-associated allergens for design of immunotherapy

Martin D. Chapman · Indoor Biotechnologies (United States) · funded by National Institutes of Health

$584.8kAllergic Rhinitis and Sensitization

2009–2025 · research · R01

Antigenic determinants of asthma-associated allergens for design of immunotherapy

Martin D. Chapman · Indoor Biotechnologies (United States) · funded by National Institutes of Health

$547.9kAllergic Rhinitis and Sensitization

2009–2020 · research · R01

Antigenic determinants of asthma-associated allergens for design of immunotherapy.

Martin D. Chapman · Indoor Biotechnologies (United States) · funded by National Institutes of Health

$697.8kAllergic Rhinitis and Sensitization

2009–2020 · research · R01

Antigenic determinants of asthma-associated allergens for design of immunotherapy.

Martin D. Chapman · Indoor Biotechnologies (United States) · funded by National Institutes of Health

$776.2kAllergic Rhinitis and Sensitization

2009–2020 · research · R01

Antigenic determinants of asthma-associated allergens for design of immunotherapy.

Martin D. Chapman · Indoor Biotechnologies (United States) · funded by National Institutes of Health

$602.5kAllergic Rhinitis and Sensitization

2009–2025 · research · R01

Antigenic determinants of asthma-associated allergens for design of immunotherapy

Martin D. Chapman · Indoor Biotechnologies (United States) · funded by National Institutes of Health

$537.9kAllergic Rhinitis and Sensitization

2009–2025 · research · R01

Antigenic determinants of asthma-associated allergens for design of immunotherapy

Martin D. Chapman · Indoor Biotechnologies (United States) · funded by National Institutes of Health

$642.4kAllergic Rhinitis and Sensitization

2009–2030 · research · R01

Antigenic determinants of asthma-associated allergens for design of immunotherapy

Martin D. Chapman · Indoor Biotechnologies (United States) · funded by National Institutes of Health

$775.4k

2008–2020 · research · R01

Antigenic determinants of asthma-associated allergens for design of immunotherapy.

Martin D. Chapman · Indoor Biotechnologies (United States) · funded by National Institutes of Health

$505.7kAllergic Rhinitis and Sensitization